Is primaquine useful and safe as true exo-erythrocytic merontocidal, hypnozoitocidal and gametocidal antimalarial drug?

Salud Publica de Mexico

Volumn 41, Issue 5, 1999, Pages 410-419

  López Antuñano, Francisco Javier ^a  

^a INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

Author keywords

Malaria therapy; Mexico; Plasmodium vivax infection; Primaquine

Indexed keywords

CHLOROQUINE; PRIMAQUINE; QUINOLONE DERIVATIVE;

ANTIMALARIAL ACTIVITY; CHEMOPROPHYLAXIS; CLINICAL PRACTICE; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; GAMETOCYTE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HUMAN; INTRAVASCULAR HEMOLYSIS; MALARIA; ORAL DRUG ADMINISTRATION; PLASMODIUM; RELAPSE; REVIEW; SPOROZOITE;

EID: 0344131928     PISSN: 00363634     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0036-36341999000500010     Document Type: Review

References (66)

1. López-Antuñano FJ, Schmunis GA, Ed. Malaria diagnosis. (Scientific Publication No. 512). Washington, D.C.: Pan American Health Organization, 1990.
2. Contacos PG, Collins WE, Jeffery GM, Krotoski WA, Howard WA. Studies on the characterization of Plasmodium vivax strains from Central America. Am J Trop Med Hyg. 1972;21(5):707-712.
3. Short HE, Garnham PCC. Demonstration of a persistant exo-erythrocytic cycle in Plasmodium cynomolgi and its bearing on the production of relapses. Br M J 1948;1:1225-1228.
4. Krotoski WA, Bray RS, Garnham PC, Gwadz RW, Killick-Kendrick R, Draper CC et al. Observations on early and late post-sporozoite tissue stages in primate malaria. II. The hypnozoite of Plasmodium cynomolgi bastianellii from 3 to 105 days after infection, and detection of 36-to 40-hours pre-erythrocytic forms. Am J Trop Med Hyg 1982;31(2):211-225.
5. Corradetti A. About the hypnozoites of the vivax-like group of Plasmodia. Trans R Soc Trop Med Hyg 1985;79(6):879-881.
6. Krotoski WA. The hypnozoite and malarial relapse. Prog Clin Parasitol 1989;1:1-19.
7. Krotoski WA, Collins WE, Bray RS, Garnham PC, Cogswell FB, Gwadz RW et al. Demonstration of hypnozoites in sporozoite-transmitted Plasmodium vivax infection. Am J Trop Med Hyg 1982;31(6):1291-1293.
8. Cogswell FB, Krotoski WA, Hollingdale MR, Gwadz RW. Identification of hypnozoites and tissue schizonts of Plasmodium vivax and P. cynomolgi by the immunoperoxidase method. Am J Trop Med Hyg 1983;32(6): 1454-1455.
9. Krotoski WA, Garnham PC, Cogswell FB, Collins WE, Bray RS, Gwadz RW et al. Observations on early and late post-sporozoite tissue stages in primate malaria. IV. Pre-erythrocytic schizonts and/or hypnozoites of Chesson and North Korean strains of Plasmodium vivax in the chimpanzee. Am J Trop Med Hyg 1986;35(2):263-274.
10. Krotoski WA, Garnham PC, Bray RS, Krotoski DM, Killick-Kendrick R, Draper CC, et al. Observations on early and late post-sporozoite tissue stages in primate malaria. I. Discovery of a new latent form of Plasmodium cynomolgi (the hypnozoite), and failure to detect hepatic forms within the first 24 hours after infection. Am J Trop Med Hyg 1982;31(1):24-35.
11. Bray RS, Krotoski WA, Cogswell FB, Garnham PC, Rodriguez M, Guy MW et al. Observations on early and late post-sporozoite tissue stages in primate malaria. III. Further attempts to find early forms and to correlate hypnozoites with growing exo-erythrocytic schizonts and parasitaemic relapses in Plasmodium cynomolgi bastianellii infections. Trans R Soc Trop Med Hyg 1985;79(2):269-273.
12. Jiang JB, Bray RS, Krotoski WA, Canning EU, Liang DS, Huang JC. Observations on early and late post-sporozoite tissue stages in primate malaria. V. The effect of pyrimethamine and proguanil upon tissue hypnozoites and schizonts of Plasmodium cynomolgi bastianellii. Trans R Soc Trop Med Hyg 1988;82(1):56-58. [Published erratum appears in Trans R Soc Trop Med Hyg 1988;82(2):236].
13. Cogswell FB, Collins WE, Krotoski WA, Lowrie RC Jr. Hypnozoites of Plasmodium simiovale. Am J Trop Med Hyg 1991;45(2):211-213.
14. Krotoski WA, Collins WE. Failure to detect hypnozoites in hepatic tissue containing exo-erythrocytic schizonts of Plasmodium knowlesi. Am J Trop Med Hyg 1982;31(4):854-856.
15. Telford SR Jr. Discovery of the pre-erythrocytic stages of a saurian malaria parasite, hypnozoites, and a possible mechanism for the maintenance of chronic infections throughout the life of the host. Int J Parasitol 1989;19(6):597-616.
16. Kukina IV, Akinshina GT, Anufrieva VN, Alimov AG. [Plasmodium yoeli -265 BY- new possibilities in the study of the resting stages of the malarial parasites]. Med Parazitol (Mosk) 1994;2:3-8 [Article in Russian].
17. Garnham PC. Swellengrebel lecture. Hypnozoites and 'relapses' in Plasmodium vivax and in vivax-like malaria. Trop Geogr Med 1988;40(3):187-195.
18. Cogswell FB. The hypnozoite and relapse in primate malaria.Clin Microbiol Rev 1992;5(1):26-35.
19. Silbermann MH, Stuiver PC. [The phenomenon of the delayed initial attack of tertian malaria]. NedTijdschr Geneeskd 1992;136(40):1984-1987. [Article in Dutch].
20. Zevering Y, Khamboonruang C, Rungruengthanakit K, Tungviboonchai L, Ruengpipattanapan J, Bathurst I et al. Life-spans of human T-cell responses to determinants from the circumsporozoite proteins of Plasmodium falciparum and Plasmodium vivax. Proc Natl Acad Sci U S A 1994;91(13): 6118-6122.
21. Liu D, Lou S, Shu H, Fu R, Ye B. [Effect of environmental temperature, cryopreservation and aging on Plasmodium vivax sporozoites developing into exo-erythrocytic stages]. Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih 1995;13(3):165-169. [Article in Chinese].
22. Shu H, Lou S, Liu D, Fu R. [Observation on hypnozoite of different isolates of Plasmodium vivax in cultured materials].Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih 1995;13(3):185-1 88 [Article in Chinese].
23. Liu D, Luo S, Ye B, Shu H, Fu R. [Demonstration of in vitro cultured exoerythrocytic schizonts and hypnozoites of Plasmodium vivax (Southern China isolate) by an immunoperoxidase antibody technique]. Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih 1995;13(2): 86-88. [Article in Chinese].
24. Carvalho LH, Fontes CJ, Fernandes AA, Marinuzzi HC, Krettli AU. Cross-reactive cellular immune response to circumsporozoite proteins of Plasmodium vivax and P. falciparum in malaria-exposed individuals. Parasite Immunol 1997;19(2):47-59.
25. Kirchgatter K, del Portillo HA. Molecular analysis of Plasmodium vivax relapses using the MSPI molecule as a genetic marker. J Infect Dis 1998; 177(2):511-515.
26. Thompson P, Werbel LM. Antimalarial agents: Chemistry and pharmacology. In: De Stevens G, ed. Medicinal chemistry. A series of monographs. Academic Press, Nueva York: 1972.
27. Alving AS, Powell RD, Brewer GJ, Arnold JD. Malaria 8-aminoquinolines and hemolysis. In: (Goodwin LG, Nimmo-Smith LH, ed.)Drugs Parasites and Hosts. Londres: Churchil, 1962.
28. Carson PE, Hohl R, Nora MV, Parkhurst GW, Ahmad T, Scanlan S et al. Toxicology of the 8-aminoquinolines and genetic factors associated with their toxicity in man. Bull World Health Organ 1981;59(3):427-437.
29. Carson PE. Hernolysis due to inherited erythrocyte enzyme deficiencies. Ann NY Acad Sci 1968;151(2):765-776.
30. Trenholme GH, Carson PE. Therapy and prophylaxis of malaria. JAMA 1978;240(21):2293-2295.
31. World Health Organization. Severe and complicated malaria. 2nd edition. Trans R Soc Trop Med Hyg 1990;84 suppl 2:1-65.
32. Kager PA, Zijlmans CW, Boele van Hensbroek M, Wetsteyn JC. [The treatment of malaria]. Ned Tijdschr Geneeskd 1997 Sep 13;141(37):1774-1778. [Article in Dutch].
33. Peters W. Plasmodium: Resistance to antimalarial drugs.Ann Parasitol Hum Comp 1990;65 suppl 1:103-106.
34. McCall BJ, Pearce MC. Malaria treatment in Queensland, 1992. The use of malaria treatment guidelines. Med J Aust 1994;161(4):259-262.
35. World Health Organization.Advances in malaria chemotherapy. Ginebra: WHO, 1984;Tech Rep Ser No. 711.
36. Desjardin RE, Doberstyn EB, Wernsdorfer WH. The treatment and prophylaxis of malaria. In: Malara. Wernsdorfer WH, McGregor Y, ed. Edinburgo: Churchil-Livingston, 1988.
37. López-Antuñano FJ, Schmunis GA. Plasmodia of humans. Parasitic Protozoa. San Diego: Academic Press, 1993, vol. 5:135-266.
38. World Health Organization.Immunodiagnosis in malaria. Ginebra:WHO, 1985; Document WHO/MAL/85, 1018.
39. Rieckmann KH, McNamara JV, Frischer H, Stockert TA, Carson PE, Powell RD. Gametocytocidal and sporontocidal effects of primaquine and of sulfadiazine with pyrimethamine in a chloroquine-resistant strain of Plasmodium falciparum. Bull World Health Organ 1968;38(4):625-632.
40. Lanners HN. Effect of the 8-aminoquinoline primaquine on culture-derived gametocytes of the malaria parasite Plasmodium falciparum.Parasitol Res 1991;77(6):478-481.
41. Reeve PA, Toaliu H, Kanekoa A, Hall JJ, Ganezakowski M. Acute intravascular haemolysis in Vanuatu following a single dose of primaquine in individuals with glucose-6-phosphate dehydrogenase-deficiency. J Trop Med Hyg 1992;95(5):349-351.
42. World Health Organization. Chemotherapy of malaria. Ginebra:WHO, 1955; Monograph Series No. 27.
43. World Health Organization. Expert Committee on Malaria Chemotherapy. Ginebra:WHO, 1986;Tech Rep Ser No. 735.
44. Organización Panamericana de la Salud / United States Pharmacopaeial Convention. Información de medicamentos. Ministerio de Sanidad y Consumo, España. Washington, Madrid. OPS/OMS, Publicación Científica 1989;No. 525.
45. Kapeghian JC, Verlangieri AJ. Effects of primaquine on serum biochemical and hematological parameters in anesthetized Macaca fascicularis. J Med Primatol 1984;13(2):97-103.
46. Coatney GR, Cooper WC, Young MD. Studies in human malaria XXX. A summary of 204 sporozoite-induced infections with the Chesson strain of Plasmodium vivax. J Natl Malar Soc 1950;9:381-396.
47. Motulsky AG, Yoshida A, Stamatoyannopoulos G. Variants of glucose-6-phosphate dehydrogenase. Ann NY Acad Sci 1971;6(179):636-643.
48. Carson PE, Frischer H Glucose-6-phosphate dehydrogenase-deficiency and related disorders of the pentose phosphate pathway. Am J Med 1966; 41(5)744-761.
49. Bunnag D, Karbwang J, Thanavibul A, Chittamas S, Ratanapongse Y, Chalermrut K et al. High dose of primaquine in primaquine resistant vivax malaria. Trans R Soc Trop Med Hyg 1994;88(2):218-219.
50. Warhurst DC. Why are primaquine and other 8-aminoquinolines particularly effective against the mature gametocytes and the hypnozoites of malaria? Ann Trop Med Parasitol 1984;78(2):165.
51. Doherty JF, Day JH, Warhurst DC, Chiodini PL. Treatment of P. vivax malaria-time for a change?Trans R Soc Trop Med Hyg 1997;91(1):76.
52. Luzzi GA, Warrell DA, Barnes AJ, Dunbar EM. Treatment of primaquine resistant Plasmodium vivax malaria. Lancet 1992;342(8814):310.
53. Beaudoin RL, Aikawa M. Primaquine induced changes in morphology of exo-erythrocytic stages of malaria. Science NY 1968;160(833):1233-1234.
54. Aikaw AM, Beaudoin RL. Morphological effects of 8-amnoquinolines on exo-erytrhrocytic tages of P. Fallax. Mil Med 1986;134(10):986-999.
55. Howells RE. The chemotherapy of rodent malaria XIII Fine structural changes observed in exo-erythrocytic stages of P. Berghei berghei following exposure to primaquine and menactone. Ann Trop Med Parasitol 1970;64:203-207.
56. Boulard Y. The chemotherapy of malaria XXXIV. Causal prophylaxis. Part III. Ultrastructural changes induced in exo-erythrocytic schizontes of Plasmodium yoelii by primaquine. AnnTrop Med Parastol 1983;77:555-568.
57. World Health Organization. The biology of malaria parasites. Ginebra: WHO, 1984; Tech Rep Ser No. 743.
58. Frischer H, Ahmad T, Nora MV, Carson PE, Sivarajan M, Mellovitz R et al. Biotransformation of primaquine in vitro with human K562 and bone marrow cells. J Lab Clin Med 1987;109(4):414-421.
59. Mihaly GW, Date NM, Ireton HJ, Smallwood RA. The effect of malaria infection on primaquine elimination in the isolated perfused rat liver. Biochem Pharmacol 1987;15;36(2):225-228.
60. Parkhurst GW, Nora MV, Thomas RW, Carson PE. High-performance liquid chromatographic-ultraviolet determination of primaquine and its metabolites in human plasma and urine. J Pharm Sci 1984;73(9):1329-1331.
61. Nora MV, Parkhurst GW, Thomas RW, Carson PE. High-performance liquid chromatographic - electrochemical assay method for primaquine in plasma and urine. J Chromatogr 1984May;11;307(2):451-456.
62. Brossi A, Gessner W, Hufford CD, Baker JK, Homo F, Millet P et al. Photooxidation products of primaquine. Structure, antimalarial activity and hemolytic effects. FEBS Lett 1987 Oct 19;223(1):77-81.
63. Baird JK, McCormick GJ, Canfield CJ. Effects of nine synthetic putative metabolites of primaquine on activity of the hexose monophosphate shunt in intact human red blood cells in vitro. Biochem Pharmacol 1986 Apr 1; 35(7):1099-1106.
64. Powell RD, DeGowin RL, Eppes RB, McNamara JV, Carson PE. The antimalarial and hemolytic properties of 4,4-diaminodiphenyl sulfone (DDS). Int J Lepr Other Mycobact Dis 1967 Oct;35(4):590-604.
65. Eppes RB, McNamara JV, DeGowin RL, Carson PE, Powell RD. Chloroquine-resistant Plasmodium falciparum: Protective and hemolytic effects of 4,4′-diaminodiphenylsulfone (DDS) administered daily together with weekly chloroquine and primaquine. Mil Med 1967;132(3):163-175.
66. Carson PE. Clinical, metabolic and molecular consequences of genetic disorders of the pentose phosphate pathway. Proc R Soc Med 1970 Feb; 63(2):175-176.